Last reviewed · How we verify

Omega-3 Supplementation — Competitive Intelligence Brief

Omega-3 Supplementation (Omega-3 Supplementation) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dietary supplement / Lipid-modifying agent. Area: Cardiovascular.

marketed Dietary supplement / Lipid-modifying agent GPR120, GPR40, PPAR-γ, NF-κB signaling pathway Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Omega-3 Supplementation (Omega-3 Supplementation) — Università degli Studi di Brescia. Omega-3 fatty acids reduce triglycerides and modulate inflammatory pathways by competing with arachidonic acid metabolism and inhibiting pro-inflammatory eicosanoid production.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Omega-3 Supplementation TARGET Omega-3 Supplementation Università degli Studi di Brescia marketed Dietary supplement / Lipid-modifying agent GPR120, GPR40, PPAR-γ, NF-κB signaling pathway

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dietary supplement / Lipid-modifying agent class)

  1. Università degli Studi di Brescia · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Omega-3 Supplementation — Competitive Intelligence Brief. https://druglandscape.com/ci/omega-3-supplementation. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing